Globally, the nearly trillion dollar US market for pharmaceuticals seems to be growing at a steady rate and on predictable lines. The Asian markets are showing signs of increased investor activity given the spate of increasing capacities for biologics and approvals of biosimilars in key markets. Additionally, clinical trial activities are on the rise. This trend has led several MNCs to increase their R&D activities in China, India and other emerging markets. In the past, the Asian markets have not been an easy place to conduct pharma or biotech business but the environment has improved. This session will focus on the efforts being made in Asia to support investors by creating local regulations that are more industry friendly and in sync with international norms.

Session ID: 21931